Reviva Pharmaceuticals Holdings, Inc. Basic Shares Outstanding (Weighted Average)
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Basic Shares Outstanding (Weighted Average) of 13.21 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 13.21M shares, a 423.59% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 7.02M shares, a 185.19% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was -156.93M shares.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 72.69M shares, a 115.02% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 3.63M shares, a 114.96% increase from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 1.69M shares, a 92.91% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 23.80M shares, a 21.94% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 19.52M shares, a 31.95% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 13.21M shares 10-Q · filed 2026-08-12 | 10.13M shares 10-Q · filed 2026-08-12 | -45.57M shares derived: average of 3 quarters · filed 2026-08-12 | -16.00M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | 7.02M shares 10-Q · filed 2026-05-13 | -74.95M shares derived: average of 2 quarters · filed 2026-05-13 | -25.74M shares derived: average of 3 quarters · filed 2026-05-13 | -18.67M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -156.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -42.12M shares derived: average of 2 quarters · filed 2026-03-30 | -27.24M shares derived: average of 3 quarters · filed 2026-08-12 | 3.63M shares 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | 72.69M shares 10-Q · filed 2025-11-13 | 37.60M shares derived: average of 2 quarters · filed 2026-08-12 | 57.15M shares 10-Q · filed 2025-11-13 | -2.46M shares derived: average of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | 2.52M shares 10-Q · filed 2026-08-12 | 49.85M shares 10-Q · filed 2025-08-14 | 2.49M shares 10-Q · filed 2026-08-12 | 49.25M shares 10-Q · filed 2025-08-14 | -27.51M shares derived: average of 3 quarters · filed 2026-08-12 | -12.18M shares derived: average of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | 2.46M shares 10-Q · filed 2026-05-13 | 48.64M shares 10-Q · filed 2025-05-15 | -42.53M shares derived: average of 2 quarters · filed 2026-05-13 | -17.08M shares derived: average of 3 quarters · filed 2026-05-13 | -5.17M shares derived: average of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | -87.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -26.86M shares derived: average of 2 quarters · filed 2026-03-30 | -7.72M shares derived: average of 3 quarters · filed 2026-03-30 | 1.69M shares 10-K · filed 2026-03-30 | 33.15M shares 10-K · filed 2025-04-03 | |||
| 2024-09-30 | 33.80M shares 10-Q · filed 2025-11-13 | 32.18M shares derived: average of 2 quarters · filed 2025-11-13 | 31.42M shares 10-Q · filed 2025-11-13 | 30.37M shares derived: average of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | 30.56M shares 10-Q · filed 2025-08-14 | 30.22M shares 10-Q · filed 2025-08-14 | 29.22M shares derived: average of 3 quarters · filed 2025-08-14 | 27.83M shares derived: average of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | 29.89M shares 10-Q · filed 2025-05-15 | 28.56M shares derived: average of 2 quarters · filed 2025-05-15 | 26.92M shares derived: average of 3 quarters · filed 2025-05-15 | 25.80M shares derived: average of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | 27.23M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | 25.43M shares derived: average of 2 quarters · filed 2025-04-03 | 24.43M shares derived: average of 3 quarters · filed 2025-04-03 | 23.80M shares 10-K · filed 2025-04-03 | ||||
| 2023-09-30 | 23.64M shares 10-Q · filed 2024-11-14 | 24.03M shares 10-Q · filed 2023-11-14 | 23.04M shares derived: average of 2 quarters · filed 2024-11-14 | 22.66M shares 10-Q · filed 2024-11-14 | 22.78M shares 10-Q · filed 2023-11-14 | 22.44M shares derived: average of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | 22.43M shares 10-Q · filed 2024-08-14 | 22.14M shares 10-Q · filed 2024-08-14 | 22.04M shares derived: average of 3 quarters · filed 2024-08-14 | 21.35M shares derived: average of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | 21.83M shares 10-Q · filed 2024-05-14 | 21.84M shares derived: average of 2 quarters · filed 2024-05-14 | 20.99M shares derived: average of 3 quarters · filed 2024-05-14 | 20.36M shares derived: average of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | 21.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | 20.56M shares derived: average of 2 quarters · filed 2024-04-15 | 19.86M shares derived: average of 3 quarters · filed 2024-04-15 | 19.52M shares 10-K · filed 2024-04-15 | ||||
| 2022-09-30 | 19.27M shares 10-Q · filed 2023-11-14 | 18.87M shares derived: average of 2 quarters · filed 2023-11-14 | 18.74M shares 10-Q · filed 2023-11-14 | 18.68M shares derived: average of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | 18.47M shares 10-Q · filed 2023-08-14 | 18.47M shares 10-Q · filed 2023-08-14 | 18.48M shares derived: average of 3 quarters · filed 2023-08-14 | 18.47M shares derived: average of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | 18.47M shares 10-Q · filed 2023-05-15 | 18.48M shares derived: average of 2 quarters · filed 2023-05-15 | 18.47M shares derived: average of 3 quarters · filed 2023-05-15 | 17.07M shares derived: average of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | 18.50M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 18.48M shares derived: average of 2 quarters · filed 2023-03-30 | 16.61M shares derived: average of 3 quarters · filed 2023-03-30 | 14.79M shares 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | 18.46M shares 10-Q · filed 2022-11-14 | 15.67M shares derived: average of 2 quarters · filed 2022-11-14 | 13.55M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 12.87M shares 10-Q · filed 2022-08-15 | 10.96M shares 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | 9.23M shares 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |